Purpose: This study investigated the efficacy of monotherapy versus combination of menhaden oil, a-lipoic acid, and enalapril on corneal sensation and morphometry and other neuropathy-related endpoints in a rat model of type 2 diabetes.
D
iabetic peripheral neuropathy is a major and devastating complication of diabetes. The search for an effective treatment has been challenging in part due to its complex etiology. Diabetic peripheral neuropathy has been described by some investigators to be a disease of the vasculature leading to nerve ischemia and altered nerve function. Other investigators have proposed that diabetic peripheral neuropathy is caused by a combination of metabolic defects. Additional contributors to diabetic peripheral neuropathy have been reported to include increased formation of advanced glycation end products, reduced neurotrophic support, and increased inflammatory and oxidative stress. Overall, these mechanisms and likely others cause damage to neurons, Schwann cells, and the vasculature. Ultimately, relentless damage to the nerve complex and surrounding vasculature leads to diabetic peripheral neuropathy. Given the complex etiology of diabetic peripheral neuropathy, successful treatment will likely require a combination of early detection, life-style changes, and pharmaceutical interventions targeting the mechanisms deemed most responsible for the pathogenesis.
In preclinical studies using diabetic rats, we have found that monotherapies consisting of enalapril, a-lipoic acid, or menhaden oil are effective in improving peripheral neuropathy and/or vascular impairment of epineurial arterioles of the sciatic nerve. 1, 2 However, these treatments were incapable of fully preventing diabetes-induced nerve or vascular damage. When we combined these 3 compounds in studies using a type 2 diabetic rat model and an early intervention protocol, we found the combination to be more efficacious. 1 In this study, we investigated the individual and combined effect of these same compounds after a late intervention to test for reversibility and return of function. Treatments were not initiated until after development of significant vascular and neural impairment, including a decrease in corneal sensation and loss of subepithelial corneal nerves. Thus, the study design allowed us to evaluate the reversibility of diabetes-induced peripheral neuropathy with emphasis on the corneal function and structure.
METHODS
Unless stated otherwise, all chemicals used in these studies were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO).
Animals
Male Sprague-Dawley (Harlan Sprague Dawley, Indianapolis, IN) rats aged 10 to 11 weeks were housed in a certified animal care facility, and food (Harlan Teklad, #7001, Madison, WI) and water were provided ad libitum. All institutional (ACORP #1590601) and NIH guidelines for use of animals were followed. The studies also adhered to the Association for Research in Vision and Ophthalmology statement for the use of animals in research. At 12 weeks of age, rats were separated into 2 groups and fed a control diet (Harlan Teklad, #7001, 4.25% kcal as fat, 3.0 kcal/g, Madison, WI) or a high-fat diet [D12451 (45% kcal as fat, 4.7 kcal/g); Research Diets, New Brunswick, NJ]. Rats were maintained on these diets for 8 weeks, and then rats fed with high fat were treated with streptozotocin (30 mg/kg in 0.1 M citric acid buffer, pH 4.5, i.p., EMD/Millipore, Billerica, MA) to induce hyperglycemia. Control-fed rats were treated with the vehicle. The blood glucose level was evaluated 96 hours later using glucose-oxidase reagent strips (Aviva AccuChek, Roche, Mannheim, Germany), and rats having a blood glucose level of 250 mg/dL (13.8 mM) or greater were considered to be diabetic. 3 Control and diabetic rats were maintained on their respective diets for an additional 16 weeks. Afterward, the diabetic rats were divided into 5 groups. Based on power calculations using corneal nerve sensitivity and density as the primary endpoints, it was determined that 10 rats would be required for each group. One group was designated as the untreated group. The other 4 groups received the 45 kcal% highfat diet containing menhaden oil (½ of the kcal of fat in the 45 kcal% high-fat diet was substituted with menhaden oil), enalapril [500 mg/kg in the 45 kcal% high-fat diet (BOC Sciences, Shirley, NY)], a-lipoic acid (2.5 g/kg in the 45 kcal% high-fat diet), or the combination of all 3. The modified diets were prepared by Research Diets. The doses of the agents used in the modified diets were based on a previous study. 1 These diets (treatment phase) were maintained for 12 weeks. We examined a set of control and diabetic rats at the time treatment began to establish a baseline for the pathology present after 24 weeks of the high-fat diet and 16 weeks of untreated hyperglycemia.
Glucose Tolerance
Glucose tolerance was determined by injecting rats with a saline solution containing 2 g/kg glucose, i.p., after an overnight fast as previously described. 1 
Thermal Nociceptive Response and Corneal Reactivity
The thermal nociceptive response in the hind paw was measured using the Hargreaves method as previously described. 3 Data were reported in seconds. Corneal sensation was measured using a Cochet-Bonnet filament esthesiometer in unanaesthetized rats (Luneau Ophtalmologie, France) as previously described. 4 The data were reported in centimeters of filament length.
Corneal sensation was also measured by applying buffered isotonic and hypertonic eye drops (290 and 900 mOsm/L) to unanaesthetized rats as previously described. 5 Animals were placed in a custom-made restraining apparatus and 6 CMOS cameras (Imaging Development Systems GmbH, Obersulm, Germany), 3 per each eye, were positioned to observe both eyes simultaneously. Custom software was used to synchronize video streams and obtain images (MATLAB R2012a; MathWorks Inc, Natick, MA). Video recording was started 30 seconds before the first epoch. Images from this recording period were used to establish a baseline area of eyelid opening. The first recording epoch began with the addition of 20 mL of the isotonic solution to the right eye. The recording period was for 3 minutes followed by a 5-minute recovery period. The next epoch began with the addition of the hypertonic solution. An image collector was used offline to retrieve video frames from each epoch. Fiji image analysis software was used by a masked technician to measure the visible surface area of both eyes between the upper and lower eyelids. These areas were expressed as a percentage of the baseline area of eyelid opening. These data were plotted against time, and the area under the curve (AUC) was used to quantify corneal sensitivity to topical isotonic and hypertonic saline, based on narrowing of the palpebral fissure in response to corneal nerve reactivity.
Corneal Innervation
On the day of the terminal studies, rats were weighed and anesthetized with Nembutal (50 mg/kg, intraperitoneally, Abbott Laboratories, North Chicago, IL). Subepithelial corneal nerves were imaged using the Rostock cornea module of the Heidelberg Retina Tomograph confocal microscope as previously described. 4 The investigator acquiring these images was masked with respect to identity of the animal condition. The corneal nerve fiber length was defined as the total length of all nerve fibers and branches (in millimeters) present in the acquired images standardized for the area of the image (in square millimeters). 4 The corneal fiber length for each animal was the mean value obtained from the acquired images and expressed as mm/mm 2 .
Motor and Sensory Nerve Conduction Velocity
Motor nerve conduction velocity was determined as previously described using a noninvasive procedure in the sciatic-posterior tibial conducting system. 3 Sensory nerve conduction velocity was determined using the digital nerve as described by Obrosova et al 6 Motor and sensory nerve conduction velocities were reported in meters per second.
Vascular Reactivity in Epineurial Arterioles
Videomicroscopy was used to investigate in vitro vasodilatory responsiveness of epineurial arterioles vascularizing the region of the sciatic nerve as previously described. 1 After isolation and suspension of the vessels, cumulative concentration-response relationships were evaluated for acetylcholine (10 28 -10 24 M). At the end of each dose, response curve for acetylcholine papaverine (10 25 M) was added to determine maximal vasodilation.
Intraepidermal Nerve Fiber Density in the Hind Paw
Immunoreactive nerve fiber profiles innervating the skin from the hind paw were visualized using standard confocal microscopy as previously described. 3 Profiles were counted by 2 individual investigators who were masked to the sample identity. All immunoreactive profiles were counted and normalized to the length, and data are presented as profiles/mm.
Physiological Markers
The nonfasting blood glucose level was determined with Aviva Accu-Chek strips. Serum was collected for determining levels of free fatty acid, triglyceride, free cholesterol, adiponectin, and activity of angiotensinconverting enzyme using commercial kits from Roche Diagnostics, Mannheim, Germany; Sigma Chemical Co, St. Louis, MO; Bio Vision, Mountain View, CA; Alpco, Salem, NH; and Buhlmann Laboratories AG, Schonenbuch, Switzerland, respectively. Serum was also used to determine thiobarbituric acid reactive substances (TBARS) as described by Mihara et al and modified by Siman and Eriksson. 7, 8 
Data Analysis
Results are presented as mean 6 SEM as in figure legends and tables. Comparisons between groups were conducted using a 1-way analysis of variance and the Bonferroni test for multiple comparisons (Prism software; GraphPad, San Diego, CA). P , 0.05 was considered significant.
RESULTS
In Table 1 (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/ICO/A508), data are provided for the change in weight, diet consumption, and blood glucose for control and diabetic rats in the treatment paradigm. At the beginning of the study, all rats weighed about the same. After 24 weeks of the high-fat diet and 16 weeks after streptozotocin treatment, all diabetic rats were randomized into 5 groups with 10 rats per group. Before initiation of treatment, all diabetic rats in each of the groups weighed less than the control rats. The difference was significant for 3 of the groups: untreated diabetic, diabetic to be treated with menhaden oil, and diabetic to be treated with the combination of menhaden oil, a-lipoic acid, and enalapril. During the 12-week treatment period, 5 diabetic rats (10%) were lost to the study. Three developed nodules and were euthanized. One damaged its right leg and was euthanized, and the other loss was due to sudden unexplained death. Data from these 5 rats were excluded.
During the treatment phase, we monitored diet consumption in all groups. Data in Table 1 (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/ICO/ A508) demonstrate that control rats consumed less chow than did the untreated and treated diabetic rats, but the difference was not significant. All diabetic rats consumed about the same amount of chow throughout the study, which suggests that the amount of menhaden oil, a-lipoic acid, and/or enalapril received was constant during the treatment phase.
At the end of the study, all diabetic rats weighed significantly less than control rats. Nonfasting blood glucose levels significantly increased in all diabetic rats compared with control rats at the beginning of the study, and this was not changed with any treatment. Data in Figure 1 (see Figure  1 , Supplemental Digital Content 2, http://links.lww.com/ICO/ A505) demonstrate that glucose clearance was significantly impaired in diabetic rats before treatment compared with control rats. At the end of the treatment phase, glucose clearance remained impaired in untreated diabetic rats, and this did not significantly improve with the monotherapies or combination therapies (Fig. 1) . Table 1 provides data on levels of serum lipids, TBARS, and adiponectin, and enzyme activity of angiotensin-converting enzyme at the end of the treatment phase. Serum-free fatty acid, triglyceride, and cholesterol levels and TBARS were all significantly increased in untreated diabetic rats. Monotherapy with menhaden oil, a-lipoic acid, or enalapril lowered serum lipid levels and TBARS. However, combination therapy was the most effective and completely corrected serum lipid and TBARS levels. Levels of adiponectin in serum remained unchanged in untreated diabetic rats. Treating diabetic rats with menhaden oil, a-lipoic acid, or enalapril trended to increase serum adiponectin levels, but this was not significant. However, treating diabetic rats with the combination of menhaden oil, a-lipoic acid, and enalapril significantly increased serum adiponectin levels. As expected, diabetes significantly increased serum angiotensin-converting enzyme activity, and this activity was significantly decreased by treatment with enalapril or the combination of menhaden oil, a-lipoic acid, and enalapril.
We have previously demonstrated that impaired vascular reactivity of epineurial arterioles of the sciatic nerve preceded slowing of nerve conduction velocity. 9 Data in Figure 2 (see Figure 2 , Supplemental Digital Content 3, http:// links.lww.com/ICO/A506) demonstrate that before initiation of treatments, vascular relaxation to acetylcholine by epineurial arterioles was significantly impaired. After the treatment phase, vascular relaxation to acetylcholine further decreased in untreated diabetic rats (Fig. 2) . Monotherapy with menhaden oil, a-lipoic acid, or enalapril significantly improved vascular relaxation to acetylcholine compared with untreated diabetic rats. However, monotherapy treatment did not fully restore vascular reactivity. In contrast, treating diabetic rats with the combination of menhaden oil, a-lipoic acid, and enalapril totally reversed the diabetes-induced vascular dysfunction.
The effects of treating chronic diabetic rats with menhaden oil, a-lipoic acid, enalapril, or their combination on neural function-related endpoints are provided in Table 2 and Figure 3 . Before the initiation of treatment, diabetic rats had slowed motor and sensory nerve conduction velocity, thermal hypoalgesia, decrease in intraepidermal nerve fibers in the skin of the hind paw, impaired corneal sensitivity, as determined by the Cochet-Bonnet filament esthesiometer, and decrease in corneal fiber length (Table 2 see baseline control and baseline diabetic columns). Representative images of subepithelial nerves from the cornea of a control and untreated diabetic rat are provided in Figure 3 (see Figure 3 , Supplemental Digital Content 4, http://links.lww.com/ICO/ A507). The corneal function as determined by evaluating sensitivity to a hypertonic solution was also impaired in diabetic rats before treatment (Fig. 3 see basal data) . The increase in the AUC, graphed as relative corneal sensitivity, represents a decrease in squinting in response to the hypertonic solution and thus a decrease in corneal sensitivity. In this study, and as previously reported, there was no response when an isotonic solution was applied to the cornea and the untreated left eye remained unresponsive throughout the study. 5 There was a trend for the neural endpoints to exacerbate in untreated diabetic rats during the 12-week treatment phase. In general, treating chronically diabetic rats with menhaden oil as a monotherapy was more effective than treatment with either a-lipoic acid or enalapril on neural endpoints and corneal sensitivity and structure and for some endpoints was equivalent to the combination therapy. However, overall, we found that combination therapy consisting of menhaden oil, a-lipoic acid, and enalapril was most efficacious in improving diabetic peripheral neuropathy including restoration of corneal nerve sensitivity and structure and vascular reactivity.
DISCUSSION
Determining corneal nerve sensitivity and subepithelial nerve density is being promoted as a surrogate marker and method for early diagnosis of diabetic peripheral neuropathy. 10, 11 Other than 2 studies that demonstrated corneal nerve FIGURE 1. Glucose utilization curve for control rats, untreated type 2 diabetic rats, and type 2 diabetic rats treated with menhaden oil, a-lipoic acid, enalapril, or their combination. The fasting blood glucose level at time 0 for control, untreated type 2 diabetic rats, and type 2 diabetic rats treated with menhaden oil, a-lipoic acid, enalapril, or their combination for early intervention was 92 6 3, 339 6 35*, 373 6 60*, + , 206 6 19*, 362 6 32* and 260 6 43* mg/dL, respectively, and for late intervention was 94 6 3, 325 6 24*, 355 6 51*, 250 6 27*, 324 6 36*, and 280 6 43* mg/dL, respectively (*P , 0.05, compared with control rats). Data are indicated as mean 6 SEM. The AUC was significantly different, P , 0.05 (impaired), for untreated type 2 diabetic rats and type 2 diabetic rats treated with menhaden oil, a-lipoic acid, enalapril, or the combination versus control rats. The number of rats in each group was the same as shown in Table 1 . regeneration 1 year after pancreas or pancreas/kidney transplant, little is known about the ability of corneal nerves to regenerate and regain functional sensitivity once the nerve function and structure are compromised by chronic untreated diabetes and/or serve as a biomarker of recovery for other diabetic neuropathy endpoints. 12, 13 The goal of this study was to determine whether optimal treatment conditions could restore corneal nerve density and functional sensitivity as well as other diabetic neuropathy endpoints once significantly impacted by chronic hyperglycemia. For these studies, we used a rat model of type 2 diabetes. 3 Interventions were started after 24 weeks of a high-fat diet and 16 weeks of hyperglycemia. The treatment paradigm included monotherapy of optimal doses of menhaden oil, a-lipoic acid, or enalapril as well as the combination of all 3 compounds. 1 Previously we have reported that these 3 compounds individually had beneficial effects on diabetic peripheral neuropathy and each has also been shown to be safe for use in humans. 1, 3, [14] [15] [16] [17] [18] Furthermore, we have shown that combining these 3 compounds was more efficacious in treating diabetic peripheral neuropathy than monotherapy. 1 However, this previous study was performed using an early intervention protocol and was designed to determine whether treatments could slow progression of diabetic peripheral neuropathy. 1 The protocol used in this study was designed to determine whether these treatments could reverse pathological deficits associated with diabetic peripheral neuropathy including loss of corneal nerves and function.
Our results clearly demonstrate that vascular and neural deficits including the corneal function and nerve density that were present after chronic hyperlipidemia and hyperglycemia in a rodent model of type 2 diabetes are reversible after treatment with menhaden oil, a-lipoic acid, or enalapril and to a greater extent after treatment with their combination. Although the study design did not allow for determining the relative time line for reversal and/or improvement of these endpoints, they have shown that improvement and regeneration of the corneal nerve function, and density, respectively, can serve as a biomarker for recovery of other neuropathy endpoints. In addition, the 3 compounds used for treatment and found to be efficacious in these studies have been widely used by humans. Fish oil supplements have been used to improve cardiovascular health and have been shown to improve metabolic features associated with type 2 diabetes. [19] [20] [21] a-Lipoic acid is naturally synthesized in mammals, including humans, and is essential for aerobic metabolism. It is also manufactured and is available as an over-the-counter dietary antioxidant supplement. After a 4-year study of treatment of mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy, a-lipoic acid was not found FIGURE 2. Effect of treating diabetic rats with menhaden oil, a-lipoic acid, enalapril, or their combination on vascular relaxation by acetylcholine in epineurial arterioles. Vascular relaxation to acetylcholine was determined as described in the legend of Figure 3 . The number of rats in each group was the same as shown in Table 1 . Data are presented as the mean of % relaxation 6 SEM. *P , 0.05 compared with control rats; + P , 0.05 compared with diabetic rats. to significantly influence the primary composite endpoints but did cause clinically meaningful improvement and prevention of progression of neuropathic impairment and was well tolerated. 22 Enalapril is an angiotensin-converting enzyme inhibitor, and these inhibitors have been widely prescribed for the treatment of hypertension and diabetic nephropathy. [23] [24] [25] [26] Malik et al 27 demonstrated that the angiotensin-converting enzyme inhibitor trandolapril improved peripheral neuropathy in normotensive patients with diabetes. A useful biomarker for screening and determining what treatments may be successful for diabetic peripheral neuropathy should be amenable to wide application and be able to objectively demonstrate efficacy. Clinical studies showing regeneration of corneal nerves after pancreas and pancreas/ kidney transplantation and our preclinical studies demonstrating full recovery of corneal nerve density and significant improvement in corneal nerve sensitivity with combination therapy provide support that examination of the corneal nerve function and structure are objective and predictive outcome measures for treatment of diabetic neuropathy. 12, 13 Moreover, our preclinical studies demonstrated that monotherapy and to a greater extent combination therapy efficaciously improved corneal nerve sensitivity and density and also reversed vascular and neural deficits associated with diabetic peripheral neuropathy.
In our study, rats were fed a high-fat diet for 24 weeks and were hyperglycemic for 16 weeks before treatment. Diabetes-induced decrease in the vascular function and nerve conduction velocity occurs early in rodents followed by thermal hypoalgesia, decrease in intraepidermal nerve fibers, and decrease in the corneal nerve function and density. 3, 9, [28] [29] [30] Therefore, our ability to demonstrate that combination therapy after chronic hyperlipidemia and hyperglycemia could reverse all these deficits whether they occur early or later in duration of diabetes and that improvement of corneal nerve sensitivity and nerve density could predict these outcomes provides proof of concept that determination of the corneal nerve function and structure may be the sensitive marker needed to monitor progression and treatment of diabetic peripheral neuropathy.
We recently introduced impairment of corneal sensitivity to a hypertonic solution as an objective marker for diabetic peripheral neuropathy. 5 In that study, we demonstrated that loss of corneal nerves in the subepithelial layer had a significant degree of correlation with the loss of corneal sensitivity. Impaired corneal sensitivity to a hypertonic solution also significantly correlated with the conventional diabetic neuropathy endpoints of slowing of motor and sensory nerve conduction velocity, thermal hypoalgesia, and decrease in epidermal nerve fiber density. 5 In this study, we show that improvement of corneal sensitivity to a hypertonic solution impaired by chronic diabetes is accompanied by regeneration of subepithelial corneal nerves. We observed minimal improvement when the chronically diabetic rats were treated with a-lipoic acid or enalapril alone, but significant improvement was achieved by treating diabetic rats with menhaden oil alone and to a greater extent the combination of menhaden oil, a-lipoic acid, and enalapril.
Mechanisms contributing to neural dysfunction in diabetes that may be improved by these treatments would likely be oxidative and inflammatory stress. Our studies demonstrated that these treatments, with combination therapy being most efficacious, reduced serum levels of free fatty acids, triglycerides, and cholesterol and TBARS, a marker of oxidative stress. It is unknown how altered lipid levels may contribute to diabetic neuropathy but diet-induced obese rats have been shown to have sensory neuropathy comparable to diabetes. 28 The mechanism responsible for the improvement of serum lipids by the monotherapies and to a greater extent combination therapy is also unknown but would seem to be due in part to improvement of oxidative and inflammatory stress. It is known that the metabolites of n-3 polyunsaturated fatty acids have antiinflammatory and neuroprotective properties. [31] [32] [33] We have previously shown that enalapril and a-lipoic acid reduce markers of oxidative stress in blood vessels and serum of diabetic rats. 34, 35 We have also shown that enriching diets of diabetic rodents with menhaden oil reduces the n-6 to n-3 fatty acid ratio and increases production of the docosahexaenoic metabolite resolvin D1. 2, 18 Additionally, we have shown that direct treatment of type 2 diabetes in a mouse model with daily injections of resolvin D1 improved diabetic peripheral neuropathy including intraepidermal nerve fiber density and density of subepithelial corneal nerve fibers and increased neurite outgrowth in cultured dorsal root ganglion neurons. 18 In summary, this study has shown that treating type 2 diabetic rats after chronic hyperlipidemia and hyperglycemia with either menhaden oil, a-lipoic acid, or enalapril or to a greater extent their combination can induce corneal nerve FIGURE 3. Effect of treating diabetic rats with menhaden oil, a-lipoic acid, enalapril, or their combination on corneal reactivity to a hypertonic solution. Corneal reactivity was determined and quantified as described in the Methods section. The data set labeled as basal was obtained from control and diabetic rats examined before initiation of treatments (n = 6). The number of rats for the treatment groups was the same as shown in Table 1 . Data are presented as the AUC. A larger AUC occurs with little squinting and lack of narrowing of the interpalpebral area because of loss of corneal sensation in response to a hypertonic saline drop. *P , 0.05 compared with control rats; + P , 0.05 compared with diabetic rats. regeneration and recovery of sensitivity. Furthermore, treatments with combination therapy overall being most efficacious also restored other endpoints associated with diabetic neuropathy and improved vascular reactivity of epineurial arterioles. We propose that clinically combination therapy will provide the most effective approach for treating diabetic neuropathy and that analysis of corneal sensitivity and corneal nerve density of the subepithelial layer may be a useful biomarker for evaluating recovery.
